The SCIEX SelexION differential mobility separation (DMS) technology is a breakthrough in ion mobility separation for improving limits of quantitation…
Afshin Safavi, Founder and Global Chief Scientific Officer at BioAgilytix (NC, USA) shares his perspective on the past, present and future of bioanalytical outsourcing.
In this final video the Business of bioanalysis panelists discuss the impact of mergers, acquisitions, and organic growth on bioanalytical sciences. The scientific community in which we work goes beyond affiliation, movement of bioanalytical scientists and talent between CRO, pharmaceutical and instrument vendors. The business is robust, while management of corporate culture is critical.
In part 2 of the Business of Bioanalysis panel discussion 2017 our panelists discuss managing the pipeline of bioanalytical talent and staff, including recruiting, training and retaining key analytical experts. Universities are not the singular source generating talent in bioanalysis skill sets. Beyond compensation, continuous education, cross-training, job rotations, and customized recognition models, within the laboratory, are critical to enticing and retaining ‘the best’ in our CRO and pharmaceutical organizations.
In part 1 of this 3-part video filmed in Los Angeles (CA, USA) our panel of experts discuss investing in emerging bioanalytical technologies – when is too soon and when is too late? Acquisition of new tools to address unmet analytical needs requires practical considerations, such as platform reliability, scalability from discovery to the regulated environment and total cost of ownership.
Bioanalysis Zone and Bioanalysis attended the 11th WRIB meeting in Los Angeles (CA, USA) and had the opportunity to host a panel discussion with experts from leading pharmaceutical companies and CROs to discuss several contemporary topics including: emerging technologies; recurring and talent development; and mergers and acquisitions.
In this Column, Stuart A. Kushon (Neoteryx; CA, USA) discusses what he feels is the key to successful implementation of microsampling.
We interviewed Joe Rajarao, Client Engagement Manager at IDBS, who discusses how the use of technology, specifically software, can impact the bioanalytical field.
Jeff Duggan, Director, Bioanalytical Mass Spectrometry, Boehringer-Ingelheim Pharmaceuticals (CT, USA) started his career in pharmaceutical bioanalysis over 20 years ago.…
In this interview Pegah Jalali, Principal Scientist at MilliporeSigma, gives insight into her work developing products and procedures to aid in biomarker discovery and pharmacokinetic studies using LC–MS.